China Blood Product Market size & share to 2014-2017

1
China Blood Product Industry Report, 2014-2017
-By Research In China

• Explore all reports for Coagulation Market
• _at_ http//www.rnrmarketresearch.com/reports/life-sc
  iences/diagnostics/in-vitro-diagnostics-ivd/coagul
  ation

2
China Blood Product Industry Report, 2014-2017

• Plasma resource reserves and control are crucial
  to the development of blood products industry.
  Although the closure of 16 plasma collection
  stations in Guizhou in 2011 didnt cause major
  disruption to domestic blood products market, the
  total plasma volume in China blood products
  industry reduced by 2.8 year on year and total
  lot release volume declined by 7 from a year
  earlier in 2013, due to stock consumption,
  insufficient utilization of new plasma stations
  and production break of some companies (e.g.
  Guizhou Taibang Biological Products Co., Ltd and
  Guangdong Wellen Biological Pharmaceutical Co.,
  Ltd. on account of upgrading and reconstruction,
  Shanghai RAAS Blood Products Co., Ltd. affected
  by floods).
• However, some niche varieties of blood products,
  such as scarce human coagulation factor VIII,
  maintained higher growth in lot release volume.
  In 2013, the human coagulation factor VIII
  produced by Shandong Taibang and CNBG Shanghai
  Institute of Biological Products were approved
  for release and came into the market, making the
  lot release volume of the product during the same
  period amount to 526,000 bottles, soaring by
  44.5 on year-on-year basis.
• Buy a copy of report _at_ http//www.rnrmarketresearc
  h.com/contacts/purchase?rname195432 .

3
China Blood Product Industry Report, 2014-2017

• Because of robust demand from China blood product
  market, the total lot release volume of imported
  human albumin reached 14.39 million bottles
  (about 10g/bottle) in 2013, a year-on-year
  increase of 24.1, accounting for 53.4 (45.3 in
  2012) of the total lot release volume of human
  albumin during the same period. Assuming absolute
  superiority, Behring, Baxter, Grifols and
  Octapharma still held the ground as the top four
  exporters of human albumin to China.
• Despite a slight year-on-year decline in output
  and sales volume, major Chinese blood products
  companies, by and large, maintained steady
  revenue growth in 2013, thanks to rising prices
  of blood products (the highest retail prices of
  fibrinogen and blood coagulation factor VIII rose
  over 50 year on year). China Biologic Products,
  Hualan Bio, Tiantan Biological Products, Shanghai
  RAAS and Yuanda Shuyang Pharmaceutical, which
  hold combined 60 of the total plasma volume,
  generated total revenue of about RMB4.2 billion
  in 2013, up 13.5 year on year. Among them,
  Shanghai RAAS, due to production halt caused by
  flood, earned only RMB496 million, down 25.1
  year on year.
• Complete report available _at_ http//www.rnrmarketre
  search.com/china-blood-product-industry-report-201
  4-2017-market-report.html.

4
China Blood Product Industry Report, 2014-2017
Attracted by national policy support and high
market prosperity, qualified Chinese blood
products companies are actively engaged in
construction of new plasma stations, some of
which are expected to collect plasma by the end
of 2014. In June 2014, Wuhan Zhongyuan Ruide
Biological Product Co., Ltd. (100 controlled by
Humanwell Healthcare (Group) Co., Ltd.)s
plasmapheresis center in Chibi was approved to
collect plasma In May 2014, Hualan Bios plasma
station in Hua County, Henan Province was
approved to be set up In April 2014, Hebei Daan
Pharmaceutical (90 stake controlled by Walvax
Biotechnology Co., Ltd.) carried out on-site GMP
compliance certification for its plasma station
in Wei County At the end of 2013, Guangdong
Shuanglin Bio-pharmacys plasma stations in Xi
County and Jiang County of Shanxi were
completed. In addition, as the Ministry of
Health stipulates that the blood products
production units with registered varieties of
blood products less than 6, and the blood
products production units, which undertake
national planned immunization task, with
registered varieties of blood products less than
5, shall not apply to set up new plasmapheresis
centers. Request discount for this report _at_
http//www.rnrmarketresearch.com/contacts/discount
?rname195432
5
China Blood Product Industry Report, 2014-2017

• China Blood Products Industry Report, 2014-2017
  focuses on the following
• Market size, plasma volume, distribution of
  plasma stations, supply and demand, import and
  export, etc. of China blood products industry
• Competitive landscape, policy environment,
  development forecast, etc. of China blood
  products industry
• Supply and demand, competitive landscape, etc. of
  8 blood product segments, including human
  albumin, Human Immunoglobulin (pH4) for
  Intravenous Injection, blood coagulation factor
  and human rabies immunoglobulin (HRIG).
• Operation, blood products business and
  development prospects of 12 major Chinese blood
  products companies.
• Buy a copy of this report _at_ http//www.rnrmarketre
  search.com/contacts/purchase?rname195432.

6
China Blood Product Industry Report, 2014-2017

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com
• / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.